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AbstrAct
Recurrent chromosome breakpoints at 6q22.31, leading to truncation and 
potential loss-of-function of the NKAIN2 gene, in Chinese prostate cancer patients 
were previously identified. In this study we investigated genomic, methylation and 
expression changes of NKAIN2 in a large number of prostate cancer samples and 
determined its functional role in prostate cancer cells. Fluorescence in situ hybridization 
analysis confirmed that NKAIN2 truncation is specific to Chinese while deletion of 
the gene is frequent in both Chinese and UK prostate cancers. Significantly reduced 
expression of NKAIN2 was also detected at both RNA and protein levels. Somatic 
mutations of NKAIN2 in prostate cancer samples exist but at very low frequency, 
suggesting that it is a putative tumor suppressor gene (TSG) with haploid insufficiency. 
Our functional studies showed that overexpression of NKAIN2 in prostate cancer cells 
inhibits cellular growth by promoting cell apoptosis, and decreasing cell migration and 
invasion. Conversely, knockdown of NKAIN2 promotes prostate cancer cell growth 
by inhibiting cell apoptosis, and increasing cell migration and invasion. These data 
imply that NKAIN2 is a novel TSG whose activity is commonly reduced in prostate 
cancer. It may restrain the disease development and progression by inducing apoptosis 
and suppressing cancer cell growth, migration and invasion. This study provides new 
insights into prostate carcinogenesis and opportunities for development of novel 
therapies for prostate cancer.
                   Research Paper
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IntroductIon
Prostate cancer is the second leading cause of 
cancer death in Western men [1], accounting for 26% of 
new cases and 9% of deaths in the USA in 2015 [2]. Its 
prevalence is much higher in most Western populations 
than Asian countries, where prostate cancer studies are 
limited [1, 3]. Recently, we identified certain genomic 
alterations that differ between prostate cancer in Western 
and Chinese populations [4–6]. Further investigation 
of prostate cancer in Chinese men should lead to 
identification of novel genomic alterations that contribute 
to prostate cancer development and/or progression.
Our high-density SNP array analysis of prostate 
cancer samples collected from the UK and China revealed 
that chromosomal truncations frequently occur at known 
tumor suppressor genes (TSGs). We also identified recurrent 
chromosomal breakpoints within the Na+/K+ transporting 
ATPase interacting 2 (NKAIN2) gene located at 6q22.31 [7], 
which result in deletion of large portions of this gene. Given 
that 6q deletions covering this genomic region are common 
in many human cancers, including prostate cancer [4, 8, 9], 
NKAIN2 is a potential TSG. Interestingly, chromosomal 
truncations disrupting NKAIN2 were observed in four of 
39 Chinese samples and only in one of 32 UK samples [7], 
suggesting that NKAIN2 truncation may be more prone to 
occur in the Chinese population. However, this has yet to be 
validated in an additional series of samples. Therefore, we 
further screened larger cohorts of Chinese and UK prostate 
samples to evaluate the frequency of NKAIN2 truncation and 
deletion, as well as its expression changes, and investigated 
its cellular function in association with tumorigenesis in vitro. 
We confirmed that NKAIN2 is a frequently down-regulated 
gene in prostate cancer, particularly in Chinese cases, and 
found that it suppresses prostate cancer cell growth and 
invasion, suggesting its role as a novel putative TSG.
results
Confirmation of prevalence of NAKIN2 genomic 
alterations in prostate cancer 
To further assess the frequency of genomic alterations 
of NKAIN2, fluorescence in situ hybridization (FISH) analysis 
was performed on tissue microarrays (TMAs) containing 318 
prostate cancer samples, including 194 cases from China and 
124 cases from UK. Loss of either 5′ or 3′ FISH signal indicated 
a NKAIN2 truncation event, and loss of FISH signal for both 
probes indicated a NKAIN2 deletion event. NKAIN2 truncation 
and deletion events were detected in 9/140 (6.4%) and 46/134 
(34.3%) Chinese prostate cancer cases, respectively. split 
signals were not detected in any of the 103 UK cases for which 
FISH signals could be counted (Figure 1) confirming that the 
NKAIN2 gene is more frequently truncated in Chinese than 
UK prostate cancers (p = 0.01). Consistent with our earlier 
study, NKAIN2 gene deletion events were detected at a similar 
frequency in prostate cancer cases taken from the UK (21/89, 
23.2%) and China (no statistical significance: p = 0.10).
NKAIN2 expression is reduced in prostate cancer
mRNA expression of NKAIN2 was analyzed by 
QRT-PCR in 36 paired tumor and adjacent normal prostate 
tissue samples from Chinese patients. NKAIN2 expression 
was reduced in 25 cancer cases when compared to matched 
normal controls (Figure 2A), and overall expression was 
significantly lower in cancer than in the adjacent normal 
samples (p = 0.002)(Figure 2B). Subsequent examination 
of NKAIN2 protein expression by immunohistochemistry 
in 281 prostate cancer cases, including 161 cases from 
China and 120 cases from UK, revealed significant under-
expression when compared to the adjacent normal tissues 
(p < 0.0001)(Table 1). All UK and most Chinese (97.3%) 
normal samples were positively stained, whereas 17.5% 
and 28% of the cancer samples from UK and China, 
respectively, were negative (Table 1)(Figure 2C). 
Somatic mutations of NKAIN2 are uncommon in 
prostate cancer
Gene mutation is another mechanism leading 
to inactivation of TSGs. To detect somatic mutations 
of NKAIN2, the upstream and coding regions of 
NKAIN2 were amplified by Fluidigm Access Array and 
then analyzed using next-generation sequencing. We 
processed 60 prostate cancer samples, of which 52 had 
paired adjacent normal samples, five prostate cancer cell 
lines (PC-3, 22RV1, DU145, VCaP and LNCaP) and 
two immortalized prostate epithelial cell lines PNT1a 
and PNT2-C2. More than 100× depth was generated 
for all NKAIN2 exon regions except exon 10 and the 
promoter, for which depth around 50× was achieved. We 
identified six mutations, including three missense and 
three synonymous, in four clinical prostate cancer cases 
(Table 2). No mutations were detected in any cell line.
Promoter methylation changes in prostate cancer
To further investigate if promoter methylation 
suppresses NKAIN2 expression, we identified two CpG 
islands of 470 bp and 698 bp located from –1155 to +61 
of NKAIN2. A 251 bp promoter residing within these CpG 
islands was predicted using Proscan and its activity was 
confirmed using luciferase report gene assay in 22RV1 
and HEK293 cells (Figure 3A). Consequently, we selected 
the promoter region and the CpG island within exon 1 for 
DNA methylation analysis by pyrosequencing 21 paired 
cancer and adjacent non-malignant samples. We detected 
very low level of methylation in the exon 1 CpG sites with 
no difference between tumor and normal tissues (p = 0.8)
(Figure 3B). We failed to sequence the promoter region, 
potentially due to its very high GC content.
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Knockdown of NKAIN2 increases cell 
proliferation, migration and invasion and 
decreases apoptosis of prostate cancer cells
siRNA knockdown of NKAIN2 was employed to 
explore the TSG role of NKAIN2 and its potential cellular 
function in 22RV1 and PC3 prostate cancer cells. NKAIN2 
expression as determined by Western blotting was greater 
in 22RV1 than in PC3 cells, which could be explained 
by the deletion of NKAIN2 in PC3 but not 22RV1 cells. 
Knockdown by siRNA decreased the expression levels 
of NKAIN2 in 22RV1 and PC3 cells compared to non-
targeting siRNA transfected control cells (Figure 4A). This 
significantly enhanced the growth of 22RV1 and PC3 cells 
compared to the non-targeting siRNA transfected cells 
(Figure 4B). To investigate if this increased cell growth 
correlated with decreased cell death, we analyzed the effect 
of NKAIN2 knockdown on apoptosis by flow cytometry 
analysis and found that apoptosis was inhibited 24 h after 
knockdown of NKAIN2 (Figure 4C). Furthermore, the 
migration and invasion analyses showed that the migration 
and invasion abilities of 22RV1 and PC3 cells transfected 
with NKAIN2 siRNA significantly increased as compared to 
non-targeting siRNA transfected cells (Figure 4D and 4E).
Overexpression of NKAIN2 decreases prostate 
cancer cell proliferation, migration and invasion 
and increases apoptosis
To provide more evidence for the tumor suppressor 
role of NKAIN2, 22RV1 and PC3 cells were transiently 
overexpressed with the NKAIN2 expressing pcDNA4.0-
NKAIN2-Flag plasmid. NKAIN2 overexpression was 
confirmed by Western blot analysis using both anti-NKAIN2 
and anti-FLAG antibodies (Figure 5A). Overexpression 
of NKAIN2 significantly decreased growth and increased 
apoptosis in 22RV1 and PC3 cells compared to cells 
transfected with empty vector (Figure 5B and 5C). Using the 
transwell assay with and without matrigel, we found that cell 
invasion and migration also significantly decreased compared 
to the negative control transfected cells (Figure 5D and 5E).
dIscussIon
Deletion of the 6q region, containing several 
putative TSGs, is a frequent event in human tumors [9, 
10–12]. Our recent SNP array analysis revealed that 
genomic truncations are a common mechanism disrupting 
TSGs in prostate cancer and NKAIN2 gene is more 
frequently detected in prostate cancers from Chinese than 
UK men. Evidence from this study indicates that NKAIN2 
is a putative TSG found within the recurrently deleted 
6q chromosomal region. In addition to our data showing 
that NKAIN2 is commonly inactivated by chromosome 
alterations in prostate cancer, low mRNA expression of 
NKAIN2 has been reported in castration-resistant prostate 
cancer [13]. In neurofibromas, sub-microscopic deletions 
containing NKAIN2 were detected by microarray in 5 of 9 
samples [12]. Subsequent mining of Oncomine and Gene 
Expression Omnibus databases revealed under-expression 
of NKAIN2 in human brain, central nerve system (http://
www.oncomine.org/resource/login) and ovarian (http://
www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS3592) 
cancers compared to corresponding normal controls. These 
findings support the tumor suppressor role of NKAIN2 not 
only in prostate cancer development and progression, but 
also in other human malignancies.
NKAIN2 was found fused to SUSP1 (SUMO-1-
specific protease), creating a SUSP1:TCBA1 in a T-cell 
lymphoblastic lymphoma cell line HT-1 [14]. While the 
oncogenic function of this chimeric gene has not been 
recognized, a copy number gain and increased expression 
of NKAIN2 were found in a study of neuroblastoma [15], 
suggesting that NKAIN2 can also act as an oncogene. 
The ability of the same gene to act either as a TSG or an 
oncogene, depending on the cellular and tissue context, 
Figure 1: Fluorescence in situ hybridization (FISH) analysis on tissue microarrays to confirm recurrent NKAIN2 
breakpoints in prostate cancer. (A) Representative FISH image showing a UK case in which normal copy number of NKAIN2 was 
detected without breakpoint (two pairs of red and green signals). (b) Representative FISH image showing a Chinese case with NKAIN2 
breakpoint indicated by the loss of red signal (arrows).
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has been observed for a number of cancer associated-genes 
[16]. However, in prostate cancer, all previous studies and 
our data provided complementary evidences that NKAIN2 
is a potential TSG.
Loss of TSG function can result from genomic 
deletion, mutation and promoter DNA methylation. 
According to results from this study, chromosomal deletion 
and truncation are the two main genomic mechanisms 
leading to NKAIN2 loss of function in prostate cancer, 
whereas mutation of NKAIN2 occurs in prostate cancer 
at a low frequency. Currently, 80 mutations disrupting the 
NKIAN2 coding region have been reported in the COSMIC 
database (http://cancer.sanger.ac.uk/cosmic). From the 
COSMIC and International Genome Cancer Consortium 
(http://dcc.icgc.org/) databases, recurrence of NKAIN2 
mutation has been detected in breast (4/1233 samples), 
endometrioid (4/494), clear cell renal cell (2/878), lung 
squamous cell (4/531) and bladder (2/327) carcinomas, 
lung (7/639), esophagus (2/151) and stomach (6/338) 
adenocarcinomas, as well as skin malignant melanoma 
(13/526). Although NKAIN2 mutations were found in 
many types of cancers, its low frequency is consistent with 
Table 1: NKAIN2 immunohistochemistry results of prostate cancer cases from UK and China
uK China
– + ++ +++ Total – + ++ +++ Total
Normal 0 25 44 2 71 2 34 36 1 73 
 (0%) (35.2%) (62%) (2.8%)  (2.7%) (46.6%) (49.4%) (1.4%)  
Tumor 21 42 40 17 120 45 73 32 11 161 
 (17.5%) (35%) (33.3%) (14.2) p < 0.0001 (28%) (45.3%) (19.9%) (6.8%) p < 0.0001 
Figure 2: NKAIN2 expression is commonly decreased in prostate cancer. (A) Bar chart showing relative NKAIN2 RNA expression 
in each of the 36 cases of tumor and matched normal prostate cancer tissues from China. (b) Relative RNA expression of NKAIN2 compared 
to corresponding normal prostate tissues normalized to normal control sample 1. **p < 0.01. (c) Representative immunohistochemistry 
images for NKAIN2 protein expression in prostate cancer and adjacent normal tissues. Upper left: Strong immunostaining of the positive 
control tissue (pancreatic cancer); Upper right: Intermediate immunostaining (++) of the prostate epithelial cells in normal prostate gland 
and lack of staining in the prostate stromal cells; lower left: Lack of staining in the prostate cancer cells (–); Lower right: Strong staining of 
the prostate cancer cells (+++). All images were captured under the 20× objective lens.
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our data in prostate cancer. No difference between cancer 
and adjacent normal tissue were identified through our 
DNA methylation analysis. Since we were unsuccessful 
to determine the methylation status of the whole NKAIN2 
promoter region, the contribution of DNA methylation to 
NKAIN2 expression requires further investigation.
According to this and our previous study [7], 
genomic truncation of NKAIN2 gene occurs mainly in 
Chinese and rarely in UK prostate cancer samples. All 
chromosomal rearrangements with breakpoints at NKAIN2 
reported to date in other human malignancies, including 
neurofibromas [12], T-cell lymphoma and leukemia [14], 
were found in East Asian patients. These data suggest 
that population differences in genomic polymorphism or 
certain environmental genotoxic-carcinogenesis factors 
in the East Asian countries contribute to truncation 
of NKAIN2 during tumorigenesis. Chromosomal 
translocations at NKAIN2 gene were observed in the 
European population, including translocations t(1;6)
(q32.3;q22.3) and t(2;6)(q24.3;q22.31), which resulted 
in constitutional inactivation of NKAIN2, but they were 
detected in patients with developmental delay [17] and 
neurological disorders [18] rather than with malignancy. 
The mechanisms leading to the preference of NKAIN2 
truncations for tumorigenesis in East Asian populations 
warrant further investigation.
NKAIN2 (Na+/K+-transporting ATPase interacting 2) 
is a transmembrane protein that binds to Na+/K+-
transporting ATPase subunit beta-1 [19]. However, its 
role and cellular functions in cancer development and/or 
progression have not been investigated. By overexpression 
and knockdown of NKAIN2 in prostate cancer cells, 
we demonstrated that it suppresses cancer cell growth, 
induces apoptosis and inhibits cell migration and invasion. 
Na+/K+-ATPase, which maintains ionic homeostasis, 
recently has also been found to act as an important signal 
transducer and to form protein-protein interaction scaffold. 
Therefore, Na+/K+-ATPase is critical for regulating cell 
growth, differentiation, survival, migration and invasion as 
well as cell–cell and cell–substrate adhesion in normal and 
cancer cells [20, 21]. The beta-subunit of Na+/K+-ATPase 
is vital for the structural and functional maturation of this 
iron pump enzyme, the transport of the alpha-subunit to 
the plasma membrane and the membrane location of the 
enzyme in epithelia cells [21]. Therefore, NKAIN2 may 
suppress cancer cell growth, migration and invasion, 
Table 2: Somatic mutations in NKAIN2 identified by promoter and exon sequencing
Mutation 
Predicted 
function 
cDNA 
position 
Coding 
position 
aa 
position
aa 
change 
Effect sample 
chr6_124125363_C|T coding 78 18 6 G > G Synonymous T70
chr6_124604186_T|C coding 150 90 30 L > L Synonymous T95
chr6_124979372_G|A coding 374 314 105 R > Q missense T70
chr6_124979445_A|G coding 447 387 129 E > E Synonymous T95
chr6_125139554_A|G coding 617 557 186 D > G missense T67
chr6_124604161_T|C coding 125 65 22 L > P missense T83
Abbreviations: aa: amino acid.
Figure 3: NKAIN2 promoter activity and DNA methylation analysis. (A) The activity of the putative 251 bp NKAIN2 promoter 
detected by luciferase reporter assay in 22RV1 prostate cancer and HEK293 kidney cell lines. For each cell line, luciferase activity was 
normalized to cells transfected with the empty reporter construct. (b). The percentage of methylated DNA in the exon 1 CpG island in 21 
prostate cancer and adjacent normal tissues. 
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and induce apoptosis by inhibiting Na+/K+-ATPase 
activity through binding with its beta-subunit. Increased 
expression and activity of Na+/K+-ATPase has been 
observed in cancers and these alterations can be induced 
by carcinogen before tumor development [20, 21]. More 
interestingly, it has been reported that androgen suppresses 
the expression of Na+/K+-ATPase beta subunit, which is 
higher in androgen-independent than androgen-dependent 
human prostate cancer cell lines and xenografts [22]. 
Further studies are required to clarify if NKAIN2 
represses the function of Na+/K+-ATPase directly or 
through collaboration with androgen. Nevertheless, since 
Figure 4: The effect of NKAIN2 knockdown in 22RV1 and PC-3 cells. (A) The effects of NKAIN2 knockdown confirmed 
by western blotting. NT: nontargeting siRNA. (b) Knockdown of NKAIN2 increased cell growth rate as determined by CCK-8 assay. 
(c) Representative FACS plots analysis showing reduced cell apoptosis rate by NKAIN2 knockdown. (d) Transwell migration and 
(e) transwell invasion assays showed that NKAIN2 knockdown promoted prostate cancer cell migration and invasion. Data represent three 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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the tumor suppression effects were observed by increasing 
and decreasing NKAIN2 expression level in the AR 
negative PC3 cells, NKAIN2 can clearly suppress prostate 
cancer cell growth and migration in cells without androgen 
activity. This is consistent with the report that NKAIN2 
was down-regulated in castration resistance prostate 
cancer samples [13].
While increased activity of Na+/K+-ATPase 
promotes cancer development, its reduced expression 
and activity have also been detected in certain human 
tumors, including renal cell carcinoma, urothelial cancer 
and different types of cancer cell lines [21], which is 
in concordance with the biphasic function of NKAIN2 
as either TSG or oncogene in different cell types. As 
Na+/ K+-ATPase enhances tight junctions and cell polarity, 
its reduced activity or expression in these cancers were 
proposed to lead to epithelial-mesenchymal transition 
[23], a cell feature change important for cancer invasion 
Figure 5: The effect of NKAIN2 overexpression in 22RV1 and PC-3 cells. (A) The expression of NKAIN2 analyzed by western 
blotting, NC: negative control. (b) Cell growth significantly inhibited by NKAIN2 overexpression as determined by the CCK-8 analysis. 
(c) Representative FACS plots analysis showing increased cell apoptosis rate by overexpression of NKAIN2. (d) Transwell migration and 
(e) transwell invasion assays showed that overexpression of NKAIN2 significantly inhibited prostate cancer cell migration and invasion. 
Error bars represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
Oncotarget63800www.impactjournals.com/oncotarget
and metastasis. Further investigations are required to 
understand how NKAIN2 suppresses Na+/K+-ATPase 
functions and by which molecular pathways NKAIN2 
restrains prostate cancer development and/or progression.
The Na+/K+-ATPase inhibitors, initially used 
clinically to control heart failures, appeared to take an 
effect in preventing human cancers, including prostate 
cancer. Many such inhibitors have consequently been 
investigated in vitro and in vivo for their anti-cancer 
effects as well as cardiotoxicity, and certain inhibitors 
are currently under clinical trials [20]. However, the 
anti-cancer activity of Na+/K+-ATPase inhibitors were 
previously examined without considering its molecular 
changes in cancer cells, which is required for such 
targeted therapy. Treatment using these inhibitors and 
selected exclusively for cancers with elevated Na+/K+-
ATPase activity should increase the therapeutic efficiency 
and reduce cardiotoxicity. We demonstrated that loss of 
NKAIN2 function occurs in a large proportion of prostate 
cancer cases, which may lead to overactivity of Na+/K+-
ATPase and consequently prostate cancer development and 
progression. This promotes the development of a genomic 
or gene expression diagnostic assay with great prospect 
to identify substantial number of prostate cancer patients 
suitable for treatment with Na+/K+-ATPase inhibitors. 
Further investigations of other downstream mechanisms 
associated with the tumor suppressor activity of NKAIN2 
have the potential to identify more molecular targets for 
the development of novel therapies, which can be used 
alone or in combination with Na+/K+-ATPase inhibitors.
In conclusion, we found that NKAIN2 is commonly 
inactivated in prostate cancer, particularly in the Chinese 
cases, by genomic deletion and truncation. NKAIN2 may 
act as a tumor suppressor involved in inhibition of cancer 
cell growth, migration and invasion as well as inducement 
of apoptosis, potentially through suppressing Na+/K+-
ATPase or other molecular pathways. Identification of 
prostate cancer cases with loss of NKAIN2 functions, 
and treating them with Na+/K+-ATPase inhibitors with 
or without combination with other therapeutic drugs may 
provide an efficient therapeutic approach.
MATERIAlS AND METHODS
Cell lines and tissue specimens
Six human prostate cancer cell lines, PC-3, 22RV1, 
LNCaP, DU145, VCaP, MDAPCa2b (ATCC, Manassas, 
VA, USA), two immortalized human prostate epithelial 
cell lines, PNT1a, PNT2-C2 (obtained from Norman 
Maitland), and the human embryonic kidney cell line 
HEK293 (ATCC), were used in this study. All cell lines 
were authenticated by STR genotype analysis and cultured 
in DMEM medium with 10% bovine serum.
Ninety six paired tumor and normal fresh frozen 
prostate cancer clinical samples from China, three TMAs 
containing 124 UK prostate cancer cases and four TMAs 
containing 194 Chinese prostate cancer cases were 
included for this study. Samples were collected with 
written informed consent of the patients and approved by 
research ethics committee in UK and local institutional 
ethical review boards in China.
FISH analysis
FISH analysis was performed on TMA samples as 
previously described [4]. We applied two BACs RP11-
423J22 (5′ of NKAIN2, labeled green) and RP11-510H23 
(3′ of NKAIN2, labeled red) to detect both genomic 
truncations and copy number changes of NKAIN2. FISH 
signals were scanned and captured under a 40× lens using 
an Olympus fluorescent microscope equipped with a CCD 
camera (Olympus, Tokyo, Japan) on the Applied Imaging 
Ariol System (Leica, San Jose, CA, USA). Evaluation of 
the FISH results was performed in a double-blind manner 
and a minimum of 100 cells with clear hybridization 
signals were counted per core.
Mutation analysis by combined fluidigm 
selected genomic region amplification and 
next- generation sequencing
The genomic regions containing all 11 exons of 
NKAIN2 and a 450 bp potential promoter region were 
amplified using Fluidigm Access Array (Fluidigm, 
Cambridge, UK). PCR product from each primer pair was 
assessed by Agilent Bioanalyser and further processed for 
next-generation sequencing on an Illumina MiSeq system 
(Illumina, San Diego, CA). Sequencing data were aligned 
with Bowtie 2 [24] and variants were called with VarScan 
2 [25] using Genome Reference Consortium human build 
37 (GRCh37). A mutation was recorded only when the 
mutant allele frequency was 10 or more.
Quantitative reverse transcription PCR 
(qRT- PCR) analysis
Total RNA was extracted from fresh frozen tissues 
and cell lines using Trizol (Life technologies, Carlsbad, 
USA) following the manufacturer’s protocol. Tumor and 
matched adjacent normal tissues were macro-dissected 
to achieve satisfactory purity of cancer cells. The cDNA 
was synthesized from total RNA using Superscript II (Life 
technologies). QRT-PCR was performed using TaqMan 
Master Mix (Life Technologies) and predesigned TaqMan 
NKAIN2 expression probes (Hs00902853_m1) and the 
endogenously expressed GAPDH gene (Hs99999905_ m1) 
(Life Technology), as previously described [10]. Each 
sample was performed in triplicate.
Promoter activity and DNA methylation analysis
The putative promoter region was cloned into a 
pGL3-basic luciferase reporter construct and transfected 
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with controls into 22RV1 and HEK293 cells using 
lipofectamine 2000. The luciferase activity was detected 
using the One-Glo Luciferase Assay System (Promega, 
Madison, USA). Genomic DNA from cancer and adjacent 
normal tissue samples was bisulphite-converted with the 
Epi-Tect Bisulfite kit (Qiagen, Venlo, Netherlands). Two 
regions, one for the NKAIN2 promoter region and one for 
the CpG island located at exon 1 before the translation 
start site, were biotin-labeled to amplify the bisulphite-
converted DNA and subsequently pyrosequenced as 
previously described [26].
Generation of NKAIN2 antibody and Western 
blotting
A monoclonal mouse antibody binding to peptides 
(TPAPDWAPED, GYQGPQKTSH, HLQLQPMYMS, 
DLSKETDLIL, SFDFIGGFDS, TSVTPAPDWA, 
QGPQKTSHLQ, APEDHRYITV, EEEDSFDFIG, 
SKETDLILTF) of human NKAIN2 was generated 
through Abmart (Shanghai, China). For Western blotting 
analysis, cells were harvested and lysed in the RIPA buffer. 
The expression levels of proteins transferred onto the 
membranes were detected by antibodies against NKAIN2 
(Abmart), the Flag tag (Sigma-Aldrich) and β-actin 
(Bioword, USA) using the standard Western blotting 
method [10].
Immunohistochemistry
Immunohistochemistry was performed on TMA 
samples as previously described [10]. NKAIN2 expression 
levels were scored into four categories: negative, weak 
positive, intermediate positive and strong positive. The 
final protein expression score of a sample combined the 
intensity and percentage of positive cells, as previously 
described [6].
Plasmid and siRNA transfection 
22RV1 and PC3 were seeded in six-well plates 
(3 × 105 cells/well) (Corning Costar, Cambridge, USA) 
with RPMI 1640 medium containing 10% FBS, and 
incubated for 24 hours. Cells were then transfected with 
relevant plasmids or siRNAs using Lipofectamine 2000 
reagent (Life technologies) in Opti-MEM® I Reduced-
Serum Medium (Life technologies) according to the 
manufacturer’s protocol. For transient transfection 
to overexpress NKAIN2, cells were transfected with 
pcDNA4.0-NKAIN2-Flag or with the empty plasmid 
(Life technologies). For NKAIN2 knockdown, cells were 
transfected with NKAIN2 ON-TARGET plus SMARTpool 
siRNA or a scramble RNA negative control (Dharmacon, 
Lafayette, USA).
Cell proliferation, migration and invasion assays
The proliferation of post-transfected cells was 
evaluated using a CCK-8 assay (Dojindo, Kumamoto, 
Japan) according to the manufacturer’s protocol. Briefly, 
cells were seeded in 96-well plates (3 × 103 cells/well) 
and cultured for 24, 48, 72, 96 hours before adding 10 µl 
of CCK-8 to each well. After two-hour incubation, the 
absorbance value of each well was measured using a 
SpectraMax M5 microplate reader (Molecular Devices, 
USA) at 450 nm. 
The migration and invasion ability of post-
transfected cells were measured using transwell chamber 
(Corning). 3 × 104 cells resuspended in serum-free 
medium were added to the upper chamber with and 
without Matrigel (BD Biocoat, Bedford, USA) coating 
for invasion and migration assays, respectively. Cells 
were incubated for 24 hours for migration or 48 hours 
for invasion analysis. Cells on the upper surface of the 
membrane were removed with a cotton swab. The cells on 
the lower surface were fixed, stained and counted under a 
light microscope in five randomly selected fields.
Flow cytometry analysis
Twenty-four hours after transfection, the cells were 
washed twice with cold PBS and proceeded using the 
annexin V FITC apoptosis detection kit I (BD) according 
to the manufacturer’s instructions. Apoptotic cells were 
detected by flow cytometry on the BD FACSVerse system.
Statistical analysis
Statistical analyses were performed using the SPSS 
(version 20.0) software with two tailed tests. Chi square 
test was used for categorized data, including FISH and 
immunohistochemistry results. Mann-Whitney U test 
was applied for RNA expression and DNA methylation 
data. Student’s t-test was used for functional study data 
between the positive and control transfected groups after 
NKAIN2 overexpression and knockdown in prostate 
cancer cell lines. p < 0.05 was considered to be statistically 
significant.
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